(Reuters)—Drug developer Vitae Pharmaceuticals Inc. said its experimental psoriasis drug significantly reduced the skin condition in patients from a mid-stage trial, sending its shares up 70% in after-hours trading. Patients taking a 350 mg dose of the drug, VTP-43742, showed a 24% reduction, while patients who took the 700 mg dose showed a 30% reduction…
Johnson & Johnson Hit with $500 Million Verdict in Trial over Hip Implants
NEW YORK (Reuters)—Johnson & Johnson and its DePuy unit were ordered by a Texas federal jury on Thursday to pay a total of about $500 million to five plaintiffs who said they were injured by Pinnacle metal-on-metal hip implants. Following a two-month trial, jurors found that the Pinnacle hips were defectively designed, and that the…
Smartphones Not So Smart with Urgent Medical Questions
(Reuters Health)—Smartphones are the first thing many people turn to with questions about their health. But when it comes to urgent queries about issues like suicide, rape and heart attack, phones can be pretty bad at offering good medical advice, a new study suggests. Researchers tested four commonly used conversation agents that respond to users’…
Clinical Trials: Zilretta Promising for Knee OA Pain & Golimumab Completes Phase 3 Trial
In recent Phase 3 clinical trials, Zirletta proved effective in managing pain for patients with knee osteoarthritis, and subcutaneous golimumab helped patients with psoriatic arthritis achieve long-term functional improvement…
Oxidized Mitochondrial DNA May Contribute to Inflammation in SLE
New research examines how the generation of reactive oxygen species and neutrophil extracellular traps may break down the protective mechanisms of mitochondrial DNA, resulting in NETosis in people with autoimmune disease. They found oxidized mitochondrial DNA may contribute to inflammation in such diseases as systemic lupus erythematosus by upregulating type I interferon signatures…
Women Lag Men as Lead Authors in Top Medical Journals
(Reuters Health)—Women are more apt to be lead authors of research in major medical journals today than they were a generation ago, but they still lag significantly behind men, a recent study suggests. The gender gap matters because lead authors make key decisions on what topics to research, who to include in studies, which outcomes…
From the Expert: New Insights into Treating Pregnant Patients with Rheumatic Disease
The approach of under-treating rheumatic disease in pregnant patients is changing, according to Bonnie Lee Bermas, MD. Dr. Bermas discusses with The Rheumatologist the need for more research on how drugs affect this patient group, and how timing of conception and disease stability play important roles in the safe outcomes of mother and infant…
U.S. Health Agency Estimates 2015 Prescription Drug Spending Rose to $457 Billion
NEW YORK (Reuters)—Spending on prescription drugs is projected to have risen to $457 billion in 2015 and will likely continue to grow as a percentage of overall healthcare spending, a U.S. government health agency said on Tuesday. That is an increase of about 8% from 2014’s prescription drug spending, which is also an estimated figure,…
Health Apps Often Lack Privacy Policies & Share Our Data
(Reuters Health)—Just because a health app has a privacy policy doesn’t mean the data will remain private, an analysis of mobile tools for diabetes suggests. In fact, privacy policies appear rare, and when they do exist, most state that user data will be collected and half warn that medical information will be shared with third…
The ACR Announces Research Agenda for 2016–2020
Future rheumatology-specific research should focus on the definition of new therapeutic targets, improving the understanding of existing therapies, engaging patients in their care and more, according to a recent assessment by the ACR’s Committee on Research…
- « Previous Page
- 1
- …
- 258
- 259
- 260
- 261
- 262
- …
- 317
- Next Page »